drugset / Trial / NCT00763750

PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

NCT00763750

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.

Timeline

Start
2008-10
Primary completion
2011-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2
Subject paclitaxel poliglumex Other / unclassified 40 mg/m2
Subject paclitaxel poliglumex Other / unclassified 50 mg/m2

Indications